News and Press Releases
Samsung Biologics completes acquisition of GSK’s manufacturing facility in Rockville, Maryland
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans...
Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: March 31, 2026
Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer
Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...
Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025
Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma
Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7 Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed UK...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2025
Er-Kim Announces Exclusive Distribution Agreement with the MEDICE Health Family For Vafseo in Central & Eastern Europe
Collaboration will support access of an alternative treatment to improve the lives of people impacted by anemia caused by chronic kidney disease 14 January 2025 -- Warsaw, Poland -- Er-Kim,...
Category: Drug Delivery, Logistics, Other, Pharmaceutical
Posted: January 14, 2025
Akat Mah. Ebulula Mardin Cad. Maya Meridien İş Merkezi No: 16 Daire: 25 34335 Beşiktaş/İstanbul
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland
AGAMREE® is approved by MHRA for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in UK 14 January 2025 -- Pratteln, Switzerland -- Santhera Pharmaceuticals...
Category: Other, Pharmaceutical
Posted: January 14, 2025
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing
Agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing 23 July 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO...
Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: July 23, 2024
GSK’s Omjjara▼ (momelotinib) is accepted for use within NHS Scotland, in line with its licence, for eligible adult myelofibrosis patients with moderate to severe anaemia
Clinicians in Scotland will now have the option to use momelotinib for the treatment of disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia Momelotinib is...
Category: Other, Pharmaceutical
Posted: June 10, 2024
GSK’s Jemperli▼ (dostarlimab) is accepted for use within NHS Scotland, in line with its licence, in eligible endometrial cancer patients in first line setting
Clinicians in Scotland will now be able to use dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced...
Category: Pharmaceutical
Posted: April 8, 2024
Jemperli (dostarlimab) becomes the first immunotherapy treatment to receive NICE recommendation for use, in line with its license, in eligible endometrial cancer patients in first line setting
This final draft guidance recommends the use of dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or...
Category: Clinical Trials, Drug Discovery
Posted: March 5, 2024
Real-World Evidence Demonstrates Feasibility and Safety of Outpatient Administration of Yescarta (axicabtagene ciloleucel)
Findings show comparable safety for patients administered axicabtagene ciloleucel in the outpatient setting in the US to inpatient infusion Real-world evidence supports further exploration of use of outpatient administration of...
Category: Clinical Trials
Posted: February 15, 2024
NICE has issued guidance for GSK’s Omjjara (momelotinib) as a treatment option for disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia
Myelofibrosis is a rare blood cancer that can result in the progressive scarring of bone marrow (fibrosis), impairing its normal function There are approximately 1,970 people living with myelofibrosis across...
Category: Clinical Trials
Posted: February 15, 2024
Medicines and Healthcare Products Regulatory Agencyauthorises GSK’s Omjjara (momelotinib) in Great Britainfor treating splenomegaly or symptoms in adultmyelofibrosis patients with moderate to severe anaemia
First JAK inhibitor treatment in Great Britain specifically indicated for both newly diagnosed and previously treated myelofibrosis patients with moderate to severe anaemia 31 January 2024 -- Middlesex, UK --...
Category: Pharmaceutical
Posted: January 31, 2024
